Biotech Values

[jq1234]

Copaxone’s claim to fame has never been stellar efficacy, but rather its modest efficacy and longstanding safety profile, which spans several decades.

I agree completely. People tend to think MS patients and neurologists are eager to switch to new approved MS drugs. That's not true at all in reality. MS drug potential is demonstrated via real life usage, not in clinical trial alone. If you look at clinical trial data alone, you wouldn't think Copaxone would have sale number like it has today.

Medpage Today has very good AAN coverage. It gives good idea how real life practice is like:

http://www.medpagetoday.com/MeetingCoverage/AAN/

Gilenya:

http://www.medpagetoday.com/MeetingCoverage/AAN/25965